Multiple-Dose Bioequivalence of Mirabegron 50 mg Prolonged-Release Tablets in Healthy Participants Under Fasting Conditions.

Status

Not yet recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522627-10-00

Enrollment

Registered

2026-03-13

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

No medical condition.

None listed

Sex/Gender

All

Age

18 Years to 64 Years

None listed

Source: EU CTIS · Data processed: Mar 14, 2026